Seegene, eliminating uncertainty in increased sales this year - Hanwha Securities

Was [Korea goyounghun financial newspaper reporter] keep the price of ₩ 50,000 Hanwha Investment & Securities BUY, saying the goal is to be eliminated due to uncertainty about revenue growth this year on the 20th Seegene.

Seegene posted a 20.2 billion won 4, 2016 Sales to strong sales of core products increased by 18.7% YoY. But return some provisions, including changes in accounting standards and operating profit and R & D-related costs increased by only 7.3 percent to 2.5 billion won the same period last year.

Hanwha Securities Jun Gi researchers to mitigate seasonal variability "denotes the sales brisk at national and European Respiratory Disease test products to seasonal effects had led the overall performance," said "sales, while sales of Digestive Diseases test products are increasingly It is expected that, "said diagnosis.

New Institute "half Since Beckman Coulter incense production producer came bogged sales to begin development (ODM) operating earnings gotta visibility will be an opportunity to reassess the value" and "the end of 2015 customers can which only 20 are 2016 year has increased steeply end of the third quarter 141 pieces, "he said.

He added "the end of 2016 published by the" Seegene Project 100 'plans to expand the line of the center existing infectious disease tests cancer diagnosis and drug resistance, "said" visible from the second half showed that the customer expansion and increased sales lead to long-term ODM to sales is expected to resolve the uncertainty "predicted high.



Financial Daily Economic News FNTIMES - unauthorized reproduction for commercial purposes in accordance with the Copyright Act, No copying, distribution,
Copyright ⓒ Korea's financial newspaper & FNTIMES.com